WST
West Declares Quarterly Dividend
Article Summary
BUY- West Pharmaceutical Services Inc. (NYSE: WST) declared its regular quarterly dividend of $0.22 per share on July 21, 2026, with the dividend payable on August 5, 20 26th to shareholders of record on July 29th.
- West Pharmaceutical Services, is a global leader in innovative solutions for injectable drug administration with over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide delivering over 41 billion components and devices each year.
- West in its fiscal year 2025 generated $3.07 billion in net sales, traded on the New York Stock Exchange and included on the Standard & Poor's 500 index.
- The dividend announcement highlights the company's position as a trusted partner to established and emerging drug developers providing safe, effective containment and delivery of life-saving and life enhancing medicines.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 11.2% | 25% | 50.0 ptsMeets Minimum (11.2%) - Passes screener |
| EPS Growth Next 5Y ? | 14.5% | 25% | 35.0 ptsBelow Screener (14.5%) - Modest outlook |
| Target Price Upside ? | 8.8% | 20% | 35.0 ptsBelow Screener (8.8%) - Target: $390.71 vs Current: $359.24 |
| Gross Margin % ? | 36.3% | 15% | 60.0 ptsSolid (36.3%) - Decent margins |
| Drawdown from 52-Wk High ? | -2.3% | 15% | 20.0 ptsBarely a Dip (-2.3%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About WST
- West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
- It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.
- This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
- This segment serves biologic, generic, and pharmaceutical drug companies.
- The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
- This segment primarily serves pharmaceutical, diagnostic, and medical device companies.
- It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors.
- West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.